Holiday to Set Tone...
Health Care: Drugs
Eli Lilly and Company (LLY: NYSE)
$54.92 -0.22 | -0.40%
05/22/13 - 04:00 PM ET
4.48M / 5.12M
Vol / Avg. Vol:55.26 / 55.14
Open / Prev. Close:54.66 - 56.06
Today's Range:39.93 - 58.41
52 Wk Range:11.80%
Performance YTD:TheStreet Rating:
Portfolios with LLY
- Portfolio NameUser Type
- ContributorHigh Volume Technicals for ...
- ProRenaissance Technologies
- Contributor8 Stocks With Big Dividends...
- ContributorStocks Rising On Unusual Vo...
- ContributorRocket Stocks for the Week ...
- UserJS&JH
- Contributor5 Bullish Stocks to Buy on ...
- UserBG Stockpickr Wish List
- UserStock Interests, Ideas & Re...
- Contributor7 High-Yield Stocks With Bu...
Latest LLY Headlines from TheStreet
- Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) 05.21.13 | 10:05 am
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward 05.16.13 | 01:05 pm
- Eli Lilly And Company (LLY): Today's Featured Drugs Winner 05.15.13 | 05:05 pm
- 4 Stocks Going Ex-Dividend Tomorrow: GIL, ACC, ADM, LLY 05.13.13 | 10:05 am
- Eli Lilly And Stock To Go Ex-dividend Tomorrow (LLY) 05.13.13 | 09:05 am
- 4 Stocks Pushing The Drugs Industry Downward 05.07.13 | 01:05 pm
- It's Pipeline That Matters Most 05.04.13 | 04:05 am
- Cramer's 'Mad Money' Recap: Good Earnings, Bad Market 05.01.13 | 08:05 pm
- Eli Lilly And Company (LLY): Today's Featured Health Care Laggard 04.30.13 | 05:04 pm
- Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) 04.30.13 | 10:04 am
Press Releases for LLY
- Lilly Acquires Novel Tau Tangle Diagnostic Program To Bolster Alzheimer's Disease Research And Development - PR Newswire 04.17.13 | 08:04 am
- Lilly Announces Positive Results Of Phase III Trials Of Dulaglutide In Type 2 Diabetes - PR Newswire 04.16.13 | 08:04 am
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Lilly Confirms Date And Conference Call For First-Quarter 2013 Financial Results Announcement - PR Newswire 04.03.13 | 04:04 pm
- Potential Lilly Investment Would Further Expand Indianapolis Insulin Manufacturing Operations - PR Newswire 04.02.13 | 08:04 am
- European Medicines Agency Accepts Marketing Authorization Application For Boehringer Ingelheim And Eli Lilly And Company's Empagliflozin*, An Investigational Type 2 Diabetes Treatment - PR Newswire 03.26.13 | 11:03 am
- Boehringer Ingelheim And Eli Lilly And Company Submit New Drug Application To FDA For Empagliflozin, An Investigational Type 2 Diabetes Treatment - PR Newswire 03.25.13 | 08:03 am
- Boehringer Ingelheim And Lilly Initiate MARLINA Clinical Trial To Evaluate Use Of Tradjenta® (linagliptin) Tablets In Patients With Type 2 Diabetes And Albuminuria - PR Newswire 03.19.13 | 08:03 am
- New Study Of Cialis® (tadalafil) Tablets Co-administered With Finasteride Meets Primary Endpoint In Men With Lower Urinary Tract Symptoms Of Benign Prostatic Hyperplasia - PR Newswire 03.18.13 | 11:03 am
- New Superiority Trial Showed LIVALO® (pitavastatin) 4 Mg Provided Significantly Greater LDL-C Reduction In HIV-Infected Adults With Dyslipidemia Versus Pravastatin 40 Mg - PR Newswire 03.07.13 | 06:03 am
Partner Headlines for LLY
- J&J Q1 Earnings Beat; Pharma Strong, Devices Weak - Investor's Business Daily 04.16.13 | 04:04 pm
- Parexel Grows Earnings With Big Pharma Partnerships - Investor's Business Daily 04.04.13 | 02:04 pm
- Can New Psoriasis Drugs Scratch Investors' Itch? - Investor's Business Daily 04.04.13 | 01:04 pm
- Is the New Abbot a Winner? - Wall St. Cheat Sheet 04.02.13 | 10:04 am
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- 6 Stocks To Accumulate For A High-Yield Stable Portfolio - Seeking Alpha 02.26.13 | 09:02 am
- 2013, A Year Of Turmoil For Eli Lilly - Seeking Alpha 02.16.13 | 09:02 am
- FDA rejects Novo Nordisk insulin remedy - Financial Times 02.12.13 | 12:02 am
- Novo Nordisk Hit By Diabetes Drug Delay; Sanofi Rises - Investor's Business Daily 02.11.13 | 05:02 pm
- Novo Nordisk: reality check - Financial Times 02.11.13 | 04:02 pm
